tert-Butyl [1-(isopropylsulfonyl)piperidin-4-yl]methylcarbamate | 1286264-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-Butyl [1-(isopropylsulfonyl)piperidin-4-yl]methylcarbamate
• 英文别名: tert-butyl N-[(1-propan-2-ylsulfonylpiperidin-4-yl)methyl]carbamate
• CAS: 1286264-48-9
• 化学式: C₁₄H₂₈N₂O₄S
• mdl: MFCD18378213
• 分子量: 320.45
• InChiKey: ZKBOQXUEENKZQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.928
• 拓扑面积：
  84.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• BENZOMORPHAN ANALOGS And Use Thereof
  申请人：Purdue Pharma L.P.

  公开号：US20170073313A1

  公开（公告）日：2017-03-16

  The invention provides compounds as represented by Formula I or I′ and pharmaceutically acceptable salts, solvates, and diastereomers thereof: Wherein R 1 , R 2 , R 2a , R 3 , and R 4 are defined in the disclosure. The invention also provides compounds of Formulae II, III, and A-H, and pharmaceutically acceptable salts, solvates, and diastereomers thereof. In certain embodiments, Compounds of the Invention are useful for treating pain, constipation, and other conditions as delineated in the disclosure. Without wishing to be bound by any theory, it is believed that Compounds of the Invention are effective in treating conditions that are modulated by activity of opioid and/or ORL-1 receptors.
• [EN] BENZOMORPHAN ANALOGS AND USE THEREOF<br/>[FR] ANALOGUES DU BENZOMORPHANE ET LEUR UTILISATION
  申请人：PURDUE PHARMA LP

  公开号：WO2015171553A1

  公开（公告）日：2015-11-12

  The invention provides compounds as represented by Formula I or I' and pharmaceutically acceptable salts, solvates, and diastereomers thereof: Wherein R1, R2, R2a, R3, and R4 are defined in the disclosure. The invention also provides compounds of Formulae II, III, and A-H, and pharmaceutically acceptable salts, solvates, and diastereomers thereof. In certain embodiments, Compounds of the Invention are useful for treating pain, constipation, and other conditions as delineated in the disclosure. Without wishing to be bound by any theory, it is believed that Compounds of the Invention are effective in treating conditions that are modulated by activity of opioid and/or ORL-1 receptors.